go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Alliance Pharmaceuticals Ireland

Alliance Pharmaceuticals Ireland
United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, Ireland
Telephone: + 44 (0)1249 466966
Fax: +44 (0)1249 466 977
Medical Information e-mail: medinfo@alliancepharma.co.uk


Summary of Product Characteristics last updated on medicines.ie: 17/04/2008
SPC Alphaderm Cream

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipients
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Alphaderm 1% & 10% w/w Cream


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Contains:

Hydrocortisone 1% w/w

Urea 10% w/w

For full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Cream

Translucent, white in appearance.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the treatment of all dry ichthyotic, eczematous conditions of the skin, including atopic, infantile, chronic allergic and irritant eczema, asteatotic, hyperkeratotic and lichenified eczema, neurodermatitis and prurigo.


Go to top of the page
4.2 Posology and method of administration

Adults, children and the elderly. A small amount should be applied topically to the preferably dry affected areas twice daily. In resistant lesions occlusive dressings may be used but this is usually unnecessary because of the self occlusive nature of the special base.


Go to top of the page
4.3 Contraindications

Primary bacterial, viral and fungal diseases of the skin and secondarily infected eczemas or intertrigo acne, perioral dermatitis, rosacea and, in general, should not be used on weeping surfaces.

Known hypersensitivity to the active ingredients or any of its excipients.


Go to top of the page
4.4 Special warnings and precautions for use

Caution should be exercised when using in children. In infants and children, long term continuous therapy should be avoided, as adrenal suppression can occur even without occlusion. Excessive absorption may occur when applied under napkins. Where possible treatment in infants should be limited to 5-7 days.

Application to moist or fissured skin may cause temporary irritation.

As with corticosteroids in general, prolonged application to the face and eyelids is undesirable and the cream should be kept away from the eyes.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

There is inadequate evidence for safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may, therefore, be a very small risk of such effects in the human foetus.


Go to top of the page
4.7 Effects on ability to drive and use machines

Alphaderm does not interfere with the ability to drive or use machines.


Go to top of the page
4.8 Undesirable effects

If used correctly Alphaderm is unlikely to cause side effects. However, the following events have been observed with topical steroids, and although are rare with hydrocortisone, may occur, especially with long-term use; spread and worsening of untreated infection; thinning of the skin; irreversible striae atrophicae and telangiectasia; contact dermatitis, perioral dermatitis; acne; mild depigmentation which may be reversible. Atrophic changes may occur in intertriginous areas or nappy areas in young children.


Go to top of the page
4.9 Overdose

Chronically, grossly excessive over-use on large areas of skin in, for example, children could result in adrenal suppression of the hypothalamic-pituitary axis (HPA) as well as topical and systemic signs and symptoms of high corticosteroid dosage. In such cases, treatment should not stop abruptly. Adrenal insufficiency may require treatment with systemic hydrocortisone. Ingestion of a large amount of Alphaderm would be expected to result in gastrointestinal irritation, nausea, and possibly vomiting. Symptomatic and supportive care should be given. Liberal oral administration of milk or water may be helpful.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Hydrocortisone is a naturally occurring glucocorticoid with proven anti-inflammatory and vasoconstrictive properties. Urea has been demonstrated to have hydrating, keratolytic and anti-pruritic properties. As such, urea has additional therapeutic effect in dry hyperkeratotic skin conditions. Alphaderm cream contains hydrocortisone and urea in a specially formulated base which assists the percutaneous transportation of the active ingredients to the site of action. Due to this formulation, Alphaderm acts as a moderately potent topical corticosteroid. The base is self-occlusive and fulfils the functions of both an ointment and a cream.


Go to top of the page
5.2 Pharmacokinetic properties

Therapeutic activity of hydrocortisone depends upon adequate penetration through the horny layer of the skin. The urea in the formulation solubilises part of the hydrocortisone and has a keratolytic effect. Both these factors increase penetration of the hydrocortisone.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

White soft paraffin

Maize starch

Isopropyl myristate

Glyceryl tribehenate

Palmitic acid

Sorbitan laurate

Polyoxyethylene fatty glyceride


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

2 years.


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

Epoxy lined aluminium tube with membrane seal and white plastic screw cap. Presented in packs of 30g and 100g.

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Alliance Pharmaceuticals Limited

Avonbridge House

Bath Road

Chippenham

Wiltshire

SN15 2BB

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 943/4/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 01 April 1978

Date of last renewal: 01 April 2008


Go to top of the page
10. DATE OF REVISION OF THE TEXT

April 2008



Link to this document from your website:
http://www.medicines.ie/medicine/4824/SPC/Alphaderm+Cream/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients

 
   Hydrocortisone & urea

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo